Results of comparison in use to alternative therapy methods for subfoveal choroidal neovascularization secondary to age-related macular degeneration;Yaşa baǧli makula dejeneresansindaki subfoveal koroid neovaskülarizasyonlarin tedavisinde kullanilan alternatif yöntemlerin karşilaştirmali sonuçlari

Retina-Vitreus

Volumn 17, Issue 4, 2009, Pages 245-250

  Erdokur, Osman ^a   Tetikoǧlu, Mehmet ^a   Öztürk, Muzaffer ^a   Elçioǧlu, Mustafa ^a  

^a OKMEYDANI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Age related macular degeneration; Intravitreal bevacizumab; Photodynamic therapy; Subfoveal choroidal neovascularization

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; PEGAPTANIB; PLACEBO; RANIBIZUMAB;

ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; REMISSION; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY;

EID: 77953466021     PISSN: 13001256     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Young RW.: Pathophysiology of age-related macular degeneration. Surv. Opthalmol. 1987;31:291-306.
2. Bird AC, Bressler NM, Bressler SB, et al.: An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol. 1995;39:367-374.
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group: Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report No. 2. Arch Ophthalmol. 2003;121:1253-1268.
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials-TAP Report no. 5. Arch Ophthalmol. 2002;120:1307-1314.
5. Verteporfin In Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy (VIP) report 2. Am J Ophthalmol. 2001;131:541-560.
6. Ng EW, Adamis AP: Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352-368.
7. VEGF Inhibiton Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration; two year results of the two prospective multicenter, controlled clinical trials. Ophthtalmology. 2006;113:1001-1006.
8. Package insert. Avastin (bevacizumab). San Francisco, CA: Genentech Inc., September 2006.
9. Goff MJ, Johnson RN, McDonald HR, et al.: Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina. 2007;27:432-438.
10. Spaide RF, Laud K, Fine HF, et al.: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
11. Feiner L, Barr EE, Shui YB, et al.: Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina. 2006;26:882-888.
12. Shahar J, Avery RL, Heilweil G, et al.: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-269.
13. Lazic R, Gabric N.: Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007;114:1179-1185.
14. Augustin AJ, Puls S, Offermann I.: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27:133-140.
15. Treatmenat of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
16. Dhalla MS, Shah GK, Blinder KJ, et al.: Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006;26:988-993.
17. Chan WM, Lai TY, Wong AL, et al.: Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol. 2006;90:337-341.
18. Spaide RF, Sorenson J, Maranan L.: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003;110:1517-1525.
19. Costa RA, Jorge R, Calucci D, et al.: Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): Results of a phase I dose-escalation study. Invest Ophthalmol Vis Sci. 2006;47:4569-4578.
20. Bashur ZF, Bazarbachi A, Schakal A.: Intravitreal bevacizumab for the manangment of neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1-9.
21. Gragoudas E, Adamis A, Cunnigham E, et al.: Pegaptanib for neovascular age-related macular degeneration. N Engl Med. 2004;351:2805-2816.
22. Augustin AJ, Schmidt-Erfurth U.: Vertoporfin therapy and triamcinolone acetonide: convergent modes of action for treatment of neovascular age related macular degeneration. Eur J Ophtalmology. 2006;16:824-834.
23. Michels S, Schmidt-Erfurth U.: Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Visc Sci. 2003;44:2147-2154.
24. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al.: Influence of photodynamic therapy on expression of vadcular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Visc Sci. 2003;44:4473-4480.
25. Heier JS, Bayer DS, Ciulle TA, et al.: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration. Curr Med Res Opin. 2006;124:1532-1542.
26. Karaçorlu S, Özdemir H, Karaçorlu M.: Patolojik miyopiye baǧli subfoveal koroid neovaskülarizasyonu olgularinda fotodinamik tedavi. T Oft Gaz. 2002;32:769-774.
27. Karaçorlu M, Karaçorlu S, Özdemir H.: Klasik koroid neovaskülarizasyonlu ve gizli koroid neovaskülarizasyonlu yaşa baǧli maküla dejenerasyonu olgilarindaki fotodinamik tedavi uygulamasinin 12 aylik takip sonuçlari. Ret-Vit. 2003;11:13-18.
28. Yetik H, Müftüoǧlu G, Akar S, ve ark.: Oküler fotodinamik tedavide 24 aylik sonuçlarimiz. Ret-Vit. 2005;13:173-178.
29. Akar S.: Koroid neovaskülarizasyonlarinin tedavisinde fotodinamik tedavi. Ret-Vit. 2005;13:9-12.
30. Menteş J.: Fotodinamik tedavi. Türkiye Klinikleri Cerrahi Tip Bilimleri. 2006;2:30-37.